STOCK MARKET BSE NSE

Sanofi, GSK receive approval for Phase 3 trial of COVID vaccine in India

The global, randomised, double-blind Phase 3 study will include more than 35,000 volunteers aged 18 years and older across sites in the US, Asia, Africa and Latin America.

Published: 08th July 2021 04:53 PM  |   Last Updated: 08th July 2021 04:53 PM   |  A+A-

So far 1.14 crore doses of vaccines were administered in Telangana, which include 16.39 lakh second doses.

Representational image(Photo | PTI)

By ANI

NEW DELHI: French pharmaceutical company Sanofi and its British partner GSK (GlaxoSmithKline plc) received approval for their Phase 3 clinical study in India, to assess the safety, efficacy and immunogenicity of their adjuvanted recombinant-protein COVID-19 vaccine candidate.

The global, randomised, double-blind Phase 3 study will include more than 35,000 volunteers aged 18 years and older across sites in the US, Asia, Africa and Latin America.

As COVID-19 vaccination becomes available, study participants are encouraged to receive an approved COVID-19 vaccine during the study, if they wish to do so. As part of the study design, all participants including the control group will be offered the study vaccine as soon as it is determined to be safe and effective.

"India is participating in Sanofi Pasteur's pivotal Phase 3 study, and subject to subsequent approvals, we should soon begin enrollment of study participants in the country," said Annapurna Das, Country Head, Sanofi Pasteur India.

"As the virus continues to evolve, we are anticipating what will be needed in the coming months and years, and accordingly, have adapted our vaccine development program. We believe our COVID-19 adjuvanted, recombinant vaccine can make a significant contribution to the ongoing fight against COVID-19 and are committed to initiating our clinical program in India, at the earliest" she added. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp